{
    "info": {
        "nct_id": "NCT03517488",
        "official_title": "A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors",
        "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors:\n\nPART A (Dose Escalation Cohorts)\n\n1. Melanoma;\n2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);\n3. Hepatocellular carcinoma;\n4. Urothelial carcinoma;\n5. Squamous cell carcinoma of the head and neck;\n6. Renal cell carcinoma (clear cell predominant type);\n7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;\n8. Non-small cell lung carcinoma;\n9. Gastric or gastroesophageal junction adenocarcinoma\n10. Mesothelioma;\n11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung\n12. Cervical cancer;\n13. Squamous cell carcinoma of the anus\n\nPART B (Dose Expansion Cohorts):\n\n1. Melanoma\n2. Renal cell carcinoma (clear cell predominant type)\n3. Non-small cell lung carcinoma\n4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL)\n5. Nasopharyngeal carcinoma\n6. Cholangiocarcinoma\n7. Basal cell carcinoma\n8. Squamous cell carcinoma of the anus\n9. Mesothelioma\n10. Ovarian or fallopian tube carcinoma\n11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)\n12. Thymoma\n13. Thymic carcinoma\n14. Squamous cell carcinoma of the penis\n15. Neuroendocrine carcinoma\n16. Vulvar cancer\n17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)\n18. Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor.\n\n    * All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies.\n    * Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1.\n    * Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue\n    * ECOG performance status of 0 - 1\n    * Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subjects currently receiving other anticancer therapies, with the exception of subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy.\n* Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.\n* Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.\n* Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).\n* Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy.\n* A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.\n* Failure to recover from any immune-related toxicity from prior cancer therapy to ≤ Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only.\n* Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2.\n* Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n* Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).\n* Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).\n* Receipt of an organ allograft.\n* Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor or adequate pre-dose fresh tumor biopsy tissue",
            "criterions": [
                {
                    "exact_snippets": "Have available adequate archival formalin-fixed paraffin-embedded block(s)/slides containing tumor",
                    "criterion": "archival formalin-fixed paraffin-embedded tumor tissue blocks/slides",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adequate pre-dose fresh tumor biopsy tissue",
                    "criterion": "pre-dose fresh tumor biopsy tissue",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed diagnosis of one of the following advanced solid tumors:",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosis of one of the following advanced solid tumors",
                    "criterion": "advanced solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Melanoma;",
            "criterions": [
                {
                    "exact_snippets": "Melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (triple-negative breast cancer; TNBC);",
            "criterions": [
                {
                    "exact_snippets": "Breast carcinoma",
                    "criterion": "breast carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "estrogen receptor ... negative",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "progesterone receptor ... negative",
                    "criterion": "progesterone receptor status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "Her2 negative",
                    "criterion": "Her2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Hepatocellular carcinoma;",
            "criterions": [
                {
                    "exact_snippets": "Hepatocellular carcinoma",
                    "criterion": "hepatocellular carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Urothelial carcinoma;",
            "criterions": [
                {
                    "exact_snippets": "Urothelial carcinoma;",
                    "criterion": "urothelial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Squamous cell carcinoma of the head and neck;",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell carcinoma of the head and neck",
                    "criterion": "squamous cell carcinoma of the head and neck",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Renal cell carcinoma (clear cell predominant type);",
            "criterions": [
                {
                    "exact_snippets": "Renal cell carcinoma (clear cell predominant type)",
                    "criterion": "renal cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": "clear cell predominant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Microsatellite instability-high or mismatch repair deficient colorectal carcinoma or endometrial carcinoma;",
            "criterions": [
                {
                    "exact_snippets": "Microsatellite instability-high ... colorectal carcinoma",
                    "criterion": "colorectal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "microsatellite instability status",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "mismatch repair deficient ... colorectal carcinoma",
                    "criterion": "colorectal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "mismatch repair status",
                            "expected_value": "deficient"
                        }
                    ]
                },
                {
                    "exact_snippets": "Microsatellite instability-high ... endometrial carcinoma",
                    "criterion": "endometrial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "microsatellite instability status",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "mismatch repair deficient ... endometrial carcinoma",
                    "criterion": "endometrial carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "mismatch repair status",
                            "expected_value": "deficient"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Gastric or gastroesophageal junction adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Gastric or gastroesophageal junction adenocarcinoma",
                    "criterion": "adenocarcinoma type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "gastric",
                                "gastroesophageal junction"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Mesothelioma;",
            "criterions": [
                {
                    "exact_snippets": "Mesothelioma;",
                    "criterion": "mesothelioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Squamous cell carcinoma of the anus",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell carcinoma of the anus",
                    "criterion": "squamous cell carcinoma of the anus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Cervical cancer;",
            "criterions": [
                {
                    "exact_snippets": "Cervical cancer;",
                    "criterion": "cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Melanoma",
            "criterions": [
                {
                    "exact_snippets": "Melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Renal cell carcinoma (clear cell predominant type)",
            "criterions": [
                {
                    "exact_snippets": "Renal cell carcinoma (clear cell predominant type)",
                    "criterion": "renal cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology subtype",
                            "expected_value": "clear cell predominant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. High-grade neuroendocrine carcinoma, including small cell carcinoma of the lung",
            "criterions": [
                {
                    "exact_snippets": "High-grade neuroendocrine carcinoma",
                    "criterion": "neuroendocrine carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "small cell carcinoma of the lung",
                    "criterion": "small cell carcinoma of the lung",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Nasopharyngeal carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Nasopharyngeal carcinoma",
                    "criterion": "nasopharyngeal carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Non-small cell lung carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Non-small cell lung carcinoma",
                    "criterion": "non-small cell lung carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Cholangiocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Cholangiocarcinoma",
                    "criterion": "cholangiocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Castrate-resistant adenocarcinoma of the prostate, defined as progressive disease after surgical castration, or progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL)",
            "criterions": [
                {
                    "exact_snippets": "Castrate-resistant adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "castrate-resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive disease after surgical castration",
                    "criterion": "disease progression after surgical castration",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior surgical castration",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progression in the setting of medical androgen ablation with a castrate level of testosterone (< 50 ng/dL)",
                    "criterion": "disease progression during medical androgen ablation with castrate testosterone",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medical androgen ablation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testosterone level",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Basal cell carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Basal cell carcinoma",
                    "criterion": "basal cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Mesothelioma",
            "criterions": [
                {
                    "exact_snippets": "Mesothelioma",
                    "criterion": "mesothelioma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "Malignant adnexal neoplasms (including, but not limited to, sebaceous carcinoma, trichilemmal carcinoma, pilomatrix carcinoma, eccrine carcinoma, hidradenocarcinoma, adnexal carcinoma with divergent differentiation, papillary digital eccrine adenocarcinoma, microcystic adnexal carcinoma, and clear cell eccrine carcinoma)",
                    "criterion": "malignant adnexal neoplasms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Thymoma",
            "criterions": [
                {
                    "exact_snippets": "Thymoma",
                    "criterion": "thymoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Squamous cell carcinoma of the anus",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell carcinoma of the anus",
                    "criterion": "squamous cell carcinoma of the anus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Subjects, except those with adenocarcinoma of the prostate, must have measurable disease by RECIST 1.1.",
                    "criterion": "measurable disease by RECIST 1.1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Non-squamous cell salivary gland carcinoma (except adenoid cystic carcinoma)",
            "criterions": [
                {
                    "exact_snippets": "Non-squamous cell salivary gland carcinoma",
                    "criterion": "salivary gland carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "non-squamous cell"
                        }
                    ]
                },
                {
                    "exact_snippets": "except adenoid cystic carcinoma",
                    "criterion": "salivary gland carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "histology exclusion",
                            "expected_value": "adenoid cystic carcinoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0 - 1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 - 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Thymic carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Thymic carcinoma",
                    "criterion": "thymic carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Vulvar cancer",
            "criterions": [
                {
                    "exact_snippets": "Vulvar cancer",
                    "criterion": "vulvar cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Neuroendocrine carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Neuroendocrine carcinoma",
                    "criterion": "neuroendocrine carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Squamous cell carcinoma of the penis",
            "criterions": [
                {
                    "exact_snippets": "Squamous cell carcinoma of the penis",
                    "criterion": "squamous cell carcinoma of the penis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All subjects' cancer must have progressed after treatment with all standard therapies or have no appropriate available therapies.",
            "criterions": [
                {
                    "exact_snippets": "cancer must have progressed after treatment with all standard therapies",
                    "criterion": "cancer progression after standard therapies",
                    "requirements": [
                        {
                            "requirement_type": "progression after standard therapies",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no appropriate available therapies",
                    "criterion": "availability of appropriate therapies",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with adenocarcinoma of the prostate must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3.",
            "criterions": [
                {
                    "exact_snippets": "adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have evaluable disease (measurable or nonmeasurable lesions) by PCWG3",
                    "criterion": "evaluable disease by PCWG3",
                    "requirements": [
                        {
                            "requirement_type": "evaluable disease status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Subjects with other solid tumors for which there is published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy but for which there is no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment may be eligible for Part B after approval by the Medical Monitor.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with other solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "other"
                        }
                    ]
                },
                {
                    "exact_snippets": "published evidence of anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy",
                    "criterion": "anti-tumor activity with anti-PD1/PDL1 and/or anti-CTLA4-directed therapy",
                    "requirements": [
                        {
                            "requirement_type": "published evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment",
                    "criterion": "FDA-approved anti-PD1/PDL1 or CTLA4-directed checkpoint inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "may be eligible for Part B after approval by the Medical Monitor",
                    "criterion": "approval by the Medical Monitor",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Non-small cell lung carcinoma;",
            "criterions": [
                {
                    "exact_snippets": "Non-small cell lung carcinoma",
                    "criterion": "non-small cell lung carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Ovarian or fallopian tube carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Ovarian or fallopian tube carcinoma",
                    "criterion": "carcinoma type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "ovarian carcinoma",
                                "fallopian tube carcinoma"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).",
            "criterions": [
                {
                    "exact_snippets": "Treatment with pembrolizumab within 4 - 12 weeks of the start of study drug",
                    "criterion": "treatment with pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to start of study drug",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects currently receiving other anticancer therapies, with the exception of subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy.",
            "criterions": [
                {
                    "exact_snippets": "Subjects currently receiving other anticancer therapies",
                    "criterion": "current receipt of other anticancer therapies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with adenocarcinoma of the prostate, who may continue luteinizing hormone-releasing hormone (LHRH) analogue therapy",
                    "criterion": "adenocarcinoma of the prostate with LHRH analogue therapy",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "adenocarcinoma of the prostate"
                        },
                        {
                            "requirement_type": "LHRH analogue therapy continuation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Receipt of an organ allograft.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of an organ allograft",
                    "criterion": "organ allograft",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy.",
            "criterions": [
                {
                    "exact_snippets": "life-threatening (Grade 4) immune-mediated AE related to prior immunotherapy",
                    "criterion": "immune-mediated adverse event related to prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 4"
                        },
                        {
                            "requirement_type": "life-threatening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).",
            "criterions": [
                {
                    "exact_snippets": "Active known or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "except that subjects are permitted to enroll if they have vitiligo",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "type 1 diabetes mellitus or residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only",
                    "criterion": "type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only",
                    "criterion": "residual hypothyroidism due to an autoimmune condition",
                    "requirements": [
                        {
                            "requirement_type": "treatability",
                            "expected_value": "treatable with hormone replacement therapy only"
                        }
                    ]
                },
                {
                    "exact_snippets": "psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy",
                    "criterion": "psoriasis",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "without systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy",
                    "criterion": "atopic dermatitis",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "without systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "another autoimmune skin condition that is managed without systemic therapy",
                    "criterion": "autoimmune skin condition",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "without systemic therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs",
                    "criterion": "arthritis",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any CTLA4 antibody within 6 weeks of the start of study drug.",
                    "criterion": "CTLA4 antibody treatment",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks before start of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.). Subjects with prostate cancer may continue LHRH analogue therapy.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.)",
                    "criterion": "treatment with other anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with prostate cancer may continue LHRH analogue therapy",
                    "criterion": "LHRH analogue therapy in prostate cancer subjects",
                    "requirements": [
                        {
                            "requirement_type": "continuation_allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging, are clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "known active CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "previously treated brain metastases ... radiologically stable, ie, are without evidence of progression for at least 4 weeks by repeat imaging",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "radiological stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically stable",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without requirement of steroid treatment for at least 14 days prior to first dose of study treatment",
                    "criterion": "previously treated brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "steroid treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "steroid-free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any checkpoint inhibitor therapy regimen that targets both PD1/L1 and CTLA-4.",
                    "criterion": "prior checkpoint inhibitor therapy targeting both PD1/L1 and CTLA-4",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with nivolumab ... within 4 weeks of the start of study drug.",
                    "criterion": "treatment with nivolumab",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.",
                    "criterion": "treatment with PDL1-directed antibody",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.",
                    "criterion": "treatment with PDL2-directed antibody",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failure to recover from any immune-related toxicity from prior cancer therapy to ≤ Grade 1, except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only.",
            "criterions": [
                {
                    "exact_snippets": "Failure to recover from any immune-related toxicity from prior cancer therapy to ≤ Grade 1",
                    "criterion": "immune-related toxicity from prior cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except if previous immune-related endocrinopathy is medically managed with hormone replacement therapy only",
                    "criterion": "previous immune-related endocrinopathy",
                    "requirements": [
                        {
                            "requirement_type": "management",
                            "expected_value": "medically managed with hormone replacement therapy only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).",
            "criterions": [
                {
                    "exact_snippets": "any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug",
                    "criterion": "systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted",
                    "criterion": "inhaled or topical corticosteroids or brief courses of corticosteroids for prophylaxis of contrast dye allergic response",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2.",
            "criterions": [
                {
                    "exact_snippets": "Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ≤ Grade 2.",
                    "criterion": "toxicity related to previous anticancer treatment (excluding immune-related toxicity)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "PART A (Dose Escalation Cohorts)",
            "criterions": []
        },
        {
            "line": "PART B (Dose Expansion Cohorts):",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}